References
- Dobbs G, Fogger SA. Caught in the crossfire of the syndemic. J Addict Nurs. 2018;29(3):205–210.
- Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality; 2019.
- Leece P, Khorasheh T, Corace K, et al. Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review. BMJ Open. 2019;9(12):e032285.
- Substance Abuse and Mental Health Services Administration (SAMHSA). FAQs: provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf. Accessed December 19, 2020.
- Green TC, Bratberg J, Finnell DS. Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment. Subst Abus. 2020;41(2):147–149.
- Krawczyk N, Fingerhood MI, Agus D. Lessons from COVID 19: are we finally ready to make opioid treatment accessible? J Subst Abuse Treat. 2020;117:108074.
- Tierney M, Delaney K, Finnell DS, Naegle M, Shatell M. Make treatment accessible for opioid use disorder during the COVID-19 pandemic. Am Nurse. 2020. https://www.myamericannurse.com/make-treatment-accessible-for-opioid-use-disorder-during-the-covid-19-pandemic/. Accessed May 11, 2020.
- Nagle M, Finnell DS, Kaplan L, et al. Opioid crisis through the lens of social justice. Nurs Outlook. 2020; 68(5):682–684.
- Matwick AL, Woodgate RL. Social justice: a concept analysis. Public Health Nurs. 2017;34(2):176–184.
- Sohn H. Racial and ethnic disparities in health insurance coverage: dynamics of gaining and losing coverage over the life-course. Popul Res Policy Rev. 2017;36(2):181–201.
- Pro G, Camplain R, Sabo S, Baldwin J, Gilbert PA. Substance abuse treatment in correctional versus non-correctional settings: analysis of racial/ethnic and gender differences. J Health Disparities Res Pract. 2018;12(3):1.
- Substance Abuse and Mental Health Services Administration (SAMHSA). The Opioid Crisis and the Black/African American Population: An Urgent Issue. Publication No. PEP20-05-02-001. Office of Behavioral Health Equity; 2020.
- AMERSA. 2020. AMERSA issues solidarity statement 06.11.20. 2020. https://amersa.org/about-us/advocacy-statements/. Accessed December 19, 2020.
- Ahamad A, Paxton B, Brar R, et al. Risk Mitigation in the Context of Dual Public Health Emergencies. 2020. https://www.bccsu.ca/wp-content/uploads/2020/04/Risk-Mitigation-in-the-Context-of-Dual-Public-Health-Emergencies-v1.5.pdf. Accessed December 19, 2020.
- Montfiore Buprenorphine Treatment Network https://www.montefiore.org/buprenorphine. Accessed December 19, 2020.
- National Sobering Collaborative https://nationalsobering.org/. Accessed December 19, 2020.
- National Harm Reduction Coalition https://harmreduction.org/. Accessed December 19, 2020.
- Compton P, Wasser TE, Cheatle M. Increased experimental pain sensitivity in chronic pain patients who developed opioid use disorder. Clin J Pain. 2020;36(9):667–674.
- Compton P. Acute pain management for patients receiving medication-assisted therapy. AACN Adv Crit Care. 2019;30(4):335–342.
- Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis – buprenorphine myths and realities. N Engl J Med. 2018;379(1):1–4.
- Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230–S242. Jun
- NIDA. 2019, July 16. Access to Addiction Services Differs by Race and Gender. https://www.drugabuse.gov/about-nida/noras-blog/2019/07/access-to-addiction-services-differs-by-race-gender. Accessed December 19, 2020.
- Bourgois P, Holmes SM, Sue K, Quesada J. Structural vulnerability: operationalizing the concept to address health disparities in clinical care. Acad Med. 2017;92(3):299–307.